The company has received the all-clear for a multinational market launch of Acuvue Oasys Max 1-Day and Acuvue Oasys Max 1-Day multifocal contact lenses.
Johnson & Johnson Vision announced Wednesday that it has received clearance from the US Food and Drug Administration (FDA), approval from Health Canada, and completed CE Mark activities for the Acuvue Oasys Max 1-Day and Acuvue Oasys Max 1-Day multifocal contact lenses.
Advertisement
The news comes during this year’s annual AOA Congress and AOSA conference: Optometry’s Meeting, in Chicago.
The new contact lenses were created to provide wearers with all day comfort and visual clarity, according to a news release. They are available in both spherical and multifocal lenses, and are designed to address numerous vision correction needs.
The release also referenced a recent survey that found that 71% of eye care professionals (ECPs) are seeing patients who are experiencing eye discomfort related to increased screentime. Further, younger patients wearing contact lenses are spending, on average, 9 hours a day in front of a screen—resulting in less blinking and more dryness and eye fatigue.
The lenses are expected to be available for wear in the US, Canada, and multiple European countries by fall, the release stated.
